Scientific Illustration of a Boltbody

Our Approach

Bolt is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Patients benefiting from the Boltbody platform

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2 positive colorectal, endometrial, gastroesophageal, and metastatic breast cancer.

Scientist working at Bolt Biotherapeutics

Our Team

Bolt is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

Scientific Illustration of a Boltbody

Our Approach

Bolt Biotherapeutics is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Patients benefiting from the Boltbody platform

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2 positive colorectal, endometrial, gastroesophageal, and metastatic breast cancer.

Scientist working at Bolt Biotherapeutics

Our Team

Bolt Biotherapeutics is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

Pipeline

Decorative divider line

Utilizing our Boltbody™ ISAC approach and myeloid biology expertise, we have a built a robust pipeline of immune-stimulating, myeloid-engaging therapeutics.

Proprietary Development Programs
Program
(Target)
IndicationDiscoveryPreclinicalPhase 1Phase 2
BDC-1001
HER2

HER2+ Colorectal, Endometrial, Gastroesophageal Cancer

Phase 2

Monotherapy & nivolumab combination studyMono and nivolumab combination

HER2+ Metastatic Breast Cancer*

Phase 2

Monotherapy & pertuzumab§ combination studyMono and pertuzumab combination§
BDC-3042
Dectin-2
  • Triple-Negative Breast Cancer
  • Clear Cell Renal Cell Carcinoma
  • Head & Neck Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer

Phase 1

Dose-escalation studyDose-escalation study
Next-Gen ISAC
Undisclosed

Range of Solid Tumors

Discovery

DiscoveryDiscovery
Next-generation Boltbody™ ISAC Collaborations

Genmab

Funds 3 bispecific Boltbody ISACs through early clinical development

Innovent

Funds 3 Boltbody ISACs through early clinical development

Toray

Funds 1 Boltbody ISAC through early clinical development

* Previously treated with Enhertu
Collaboration using Bristol-Myers Squibb’s PD-1 inhibitor nivolumab
§ Collaboration using Roche’s HER2 antagonist pertuzumab
© 2024 - Bolt Biotherapeutics - All rights reserved.